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Abstract
The design of specific inhibitors against the Hsp90 chaperone and other enzyme relies on the detailed and correct
understanding of both the thermodynamics of inhibitor binding and the structural features of the protein-inhibitor
complex. Here we present a detailed thermodynamic study of binding of aryl-dihydroxyphenyl-thiadiazole inhibitor series to
recombinant human Hsp90 alpha isozyme. The inhibitors are highly potent, with the intrinsic Kd approximately equal to
1 nM as determined by isothermal titration calorimetry (ITC) and thermal shift assay (TSA). Dissection of protonation
contributions yielded the intrinsic thermodynamic parameters of binding, such as enthalpy, entropy, Gibbs free energy, and
the heat capacity. The differences in binding thermodynamic parameters between the series of inhibitors revealed
contributions of the functional groups, thus providing insight into molecular reasons for improved or diminished binding
efficiency. The inhibitor binding to Hsp90 alpha primarily depended on a large favorable enthalpic contribution combined
with the smaller favorable entropic contribution, thus suggesting that their binding was both enthalpically and entropically
optimized. The enthalpy-entropy compensation phenomenon was highly evident when comparing the inhibitor binding
enthalpies and entropies. This study illustrates how detailed thermodynamic analysis helps to understand energetic reasons
for the binding efficiency and develop more potent inhibitors that could be applied for therapeutic use as Hsp90 inhibitors.
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Introduction
Heat shock protein 90 (Hsp90) is a component of the cellular
chaperone machinery [1,2]. There are a number of recent
developments in the understanding of the interesting and complex
mechanism of Hsp90 action [3–9]. Hsp90 is overexpressed in
cancer cells and Hsp90 inhibitors have shown selectivity for cancer
cells. Therefore, small-molecule inhibitors are being developed as
anticancer therapeutics [10–15].
Two groups of natural product inhibitors of Hsp90, based on
geldanamycin and radicicol have been discovered that bind to the
N-terminal domain ATP-binding pocket. Both natural compounds
have been used as leads to develop compounds with desired
pharmaceutical properties such as increased potency and reduced
toxicity [1,13].
Experience with the natural products generated interest in
alternative chemotypes, and the first synthetic inhibitors that
bind the ATP-binding site at the NH2 terminus of Hsp90 have
been designed based on a purine scaffold [16,17]. Based on
discovery of the novel synthetic 3,4-diarylpyrazole derivative of
resorcinol-type Hsp90 inhibitor by high-throughput screening
[18], a series of active analogues of both diarylpyrazole [19] and
diarylisoxazole inhibitors [13,20] have been generated by
structure-based design. Several groups have discovered and
successfully advanced to clinics new Hsp90 inhibitors. For
instance, new inhibitors have been designed based on benzamide
[21], on 2-aminothieno[2,3-d]pyrimidine [20] and on dihydrox-
yphenylisoindoline [22] scaffolds. Here we study the aryl-
dihydroxyphenyl-thiadiazole inhibitor [23–25] binding to
Hsp90. Their chemical structures together with other selected
Hsp90 inhibitors from the literature are shown in Figure 1.
Despite these achievements, full thermodynamic description of
the ligand binding to Hsp90 is rather fragmented despite its
importance for structure-based drug development [26,27]. The
enthalpy and heat capacity of binding correlate with structural
parameters such as hydrogen bond formation and hydrophobic
contacts more closely than the Gibbs free energy. As the ligand
binding affinity is a combined function of the binding enthalpy and
the binding entropy, an improved affinity could result when any or
both terms are designed to contribute more favorably to binding
[28–30].
To characterize thermodynamic parameters of the binding of
new resorcinol derivatives to the N-terminal domain of human
Hsp90, we used two independent methods, ITC and thermal shift
assay [31] (TSA), also known as differential scanning fluorimetry
[32] and ThermoFluorH [33]. The ITC fully characterizes the
thermodynamics of the binding reaction, including the Kd, as well
as enthalpy, entropy and heat capacity of binding [26,27,30,34].
ITC accuracy of direct determination of the observed binding
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36899Figure 1. Chemical structures of selected natural and synthetic Hsp90 inhibitors. ICPD series of compounds are the subject of this study.
doi:10.1371/journal.pone.0036899.g001
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observed enthalpy can be determined with high precision and its
value can be used for calculation of a pKb value [35,36]. On the
other hand, precise determination of observable binding constants
using the TSA is possible for any noncovalent ligand binding to
protein, even for tight ligand binding, independent of whether the
ligand stabilizes or destabilizes the protein upon binding [37,38].
Therefore, the ITC and the TSA methods complement each other
for increased precision of the measurements [39].
The binding of ligands to proteins show some degree of pH
dependence, reflecting the linkage between the binding of ligand
and the binding of protons [35,36,40]. By performing experi-
ments as a function of pH in buffers with varying ionization
enthalpy, the pKa values of the group(s) responsible for the proton
linkage in the free and liganded states can be determined
together with the protonation enthalpy for this group in these
states together with intrinsic energetic parameters of the binding.
Results
Isothermal Titration Calorimetry (ITC) of ICPD Compound
Binding to Hsp90
The energetics of ICPD compound binding to Hsp90 was
measured using ITC. Figure 2 shows a representative raw data
titration of the Hsp90 N-terminal domain (Hsp90aN) with
ICPD47 in 50 mM sodium phosphate buffer, pH 7.0, in
100 mM NaCl, at 37uC. The binding reaction was strongly
exothermic and exhibited steep slope of the ITC curve indicating
tight binding reaction. All tested ICPD compounds bound to all
tested Hsp90 constructs with the stoichiometry of one inhibitor
molecule per one protein molecule within the error of ITC
measurements (Figures 2 and 3A). There was essentially no
difference in the binding curve observed with the Hsp90aN and
the full length Hsp90 protein (Hsp90aF). Therefore, the binding
reaction to the N-terminal domain closely resembles the binding
reaction to the Hsp90aF. Table 1 lists representative ITC data for
the series of inhibitor binding to Hsp90aN and Hsp90aF at a wide
range of pH, buffer, and temperature.
The observed enthalpy of binding was highly dependent on the
buffer used in the ITC experiment (Figure 3A). For example, the
observed enthalpy was approximately 228 kJ/mol in Tris buffer
and 242 kJ/mol in phosphate buffer. These buffers have
significantly different enthalpies of deprotonation. Therefore,
there are one or many binding-linked (de)protonation events.
Furthermore, analysis of observed enthalpies for ICPD47 as a
function of pH (Figure 3B) shows a typical pH dependence
indicating a single protonation event linked to inhibitor binding.
However, the ICPD62 did not exhibit such strong protonation
event near pH7 because the pKa was significantly higher as
explained later.
The observed enthalpies of binding plotted as a function of
buffer deprotonation enthalpy (DaH, Figure 3C) yielded the
number of protons being uptaken from solution upon inhibitor
binding at various temperatures. The proton number dependence
on temperature (line slope in Figure 3C) was negligible and it was
primarily dependent on solution pH.
The c value (c = C6Kb, C is the molar concentration of the
protein, and Kb is the binding constant, when the binding
stoichiometry is 1:1) for an ITC titration must be between 1 and
1000 (or more narrowly 5 to 500) to yield the curve where the
slope is not too steep or to shallow for accurate fitting [41,42]. In
order not to exceed the c =1000, at our experimental conditions
of 6 mM protein in the calorimeter cell, we can only accurately
measure the observed binding constants up to 1.6610
8 M
21(or
8610
7 M
21) The binding is tighter at lower pH and exceeds the
limit of accurate determination of binding strength. Therefore, an
additional method could increase the precision and verify the
binding constants.
Thermal Shift Assay (TSA) of ICPD Compound Binding to
Hsp90
The thermal shift assay measures the protein-ligand binding
constant by determining the increase in the melting temperature of
the protein that is caused by the ligand [37,39,43]. Protein
unfolding is monitored by following the fluorescence of an
extrinsic probe (such as 1,8-anilinonaphtalene sulfonate, ANS)
upon increasing the temperature of the protein solution at a
constant heating rate. Soluble single-domain globular proteins
melt with a single transition that is affected by ligands. Full-length
Hsp90 yields a complicated multi-domain melting transition
profile and its analysis is not straightforward. However, the N-
terminal domain of Hsp90 yields a single transition that can be
used to study inhibitor binding to Hsp90.
Figure 4A shows ANS fluorescence curves as a function of
temperature in the absence and presence of various ICPD47
inhibitor concentrations. The concentration of Hsp90aN was
10 mM. With no inhibitor added, there is a steep increase in
fluorescence observed at approximately 50uC (pH 7.0). This
increase is due to protein unfolding that exposes hydrophobic
Figure 2. Isothermal titration calorimetry data of ICPD47
binding to Hsp90aN at pH 7.0, 376C. Panel A shows raw data
curve and Panel B shows the fitted integrated ITC data curve. The
stoichiometry of binding is approximately equal to one inhibitor
molecule per protein molecule.
doi:10.1371/journal.pone.0036899.g002
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the aqueous environment [44]. ANS actually binds through a
combination of hydrophobic and ionic interactions but the ion
pairs between the ANS sulfonate groups and the protein amino
groups are not visible by fluorescence [45,46]. Addition of
ICPD47 shifted the transition midpoint towards higher temper-
atures because the ligand stabilized the protein upon binding.
Protein melting temperatures (Tm) at various inhibitor concen-
trations were determined by fitting the protein melting curves as
described in the Materials and Methods section. The resultant
transition midpoints were plotted as a function of added ligand
concentration yielding the ligand-dosing curves (Figure 4B).
Datapoints make a sigmoidal shape curve where the steepest
increase is observed at a ligand concentration which is similar but
slightly lower than the protein concentration (10 mM). The
observed binding constant is obtained by fitting the datapoints
using Eq. (6).
Figure 4C compares TSA ligand-dosing curves for ICPD
compounds and 17-AAG. Similar curves were previously pub-
lished for radicicol [47]. The four strongly-binding ICPD
compounds exhibited a large Tm shift of more than 10uC. Exact
temperature shift is strongly concentration-dependent. The
compounds ranked in this order of Tm shift and the observed
binding constant (Kb): ICPD62. ICPD47. ICPD26. ICPD34.
The observed binding constants were equal to 1.7610
8, 8.0610
7,
3.8610
7, and 1.2610
7 M
21, respectively. The 17-AAG exhibited
a significantly weaker Tm shift with the Kb =6.0610
5 M
21.
Interpretation of Binding-linked Protonation Events
ICPD compound interaction with Hsp90 was increasingly
weaker with increasing pH. The observed binding constant, as
determined both by ITC and TSA, diminished by about 1 order of
magnitude with each pH unit (Figure 5). This decrease was
attributed to a binding-linked protonation event. The analysis of
binding-linked protonation events was done as previously
described [35,40] and applied to Hsp90 [47–49].
The pH at which the decrease in observed Kb is monitored was
not the same for various compounds. ICPD62 exhibited the
decrease in Kb_obs at greater pH than ICPD47. Compounds
ICPD62 and ICPD47 have significantly different ionization pKas,
equal to approximately 8.45 and 6.72, respectively. These pKas
could be attributed to the hydroxyl groups adjacent to chlorine in
ICPD47 and to ethyl group in ICPD62. Their values are so
different because of different electron withdrawing capacity by the
chlorine and ethyl groups in the ortho position from the hydroxyl
group.
Figure 6 shows the linked protonation event, the protonation of
the hydroxyl group at high pH, upon binding to Hsp90. The
enthalpic contributions to all linked reactions, including buffer
deprotonation and compound protonation are shown. These
linked reactions make large enthalpic contributions that should be
Figure 3. The pH and buffer effects of ICPD inhibitor binding to
Hsp90. Panel A. ICPD47 binding to Hsp90aN by ITC in three buffers: m
– sodium phosphate, % – Hepes, andN – Tris chloride buffer, at pH 7.5
and 37uC. Note that the observed enthalpy of binding is significantly
more exothermic in phosphate than in Tris buffer. This indicates the
presence of a binding-linked protonation event. Panel B. The observed
enthalpies of ICPD47 binding to Hsp90aN as a function of pH in two
buffers: m – phosphate, andN – Tris. The data points are the enthalpies
that were observed experimentally using ITC, and the lines are fitted to
the single binding-linked protonation model, Eqs. (1–4). Observed
binding enthalpies differ in the two buffers at higher pH values because
of a linked protonation event, and because Tris and phosphate have
different deprotonation enthalpies. The intrinsic binding enthalpy is the
point at which the two curves meet at low pH values (,240 kJ/mol).
Panel C. The observed enthalpies of ICPD47 binding to Hsp90aNa sa
function of the buffer deprotonation enthalpy at various temperatures:
# –1 2 uC, X –2 5 uC, n –3 7 uC, and & –4 3 uC. The data points are the
experimentally observed enthalpies, and the trendlines are linear fits.
Their slopes are equal to the binding-linked protonation events (n).
There was little change of n as a function of temperature. The zero
intercepts of the lines are equal to the buffer-independent binding
enthalpies. The enthalpies are not intrinsic binding enthalpies because
they contain the heats of protonation of protein/ligand functional
groups.
doi:10.1371/journal.pone.0036899.g003
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compounds to recombinant human Hsp90 protein constructs
as a function of pH, temperature, and buffer ionization
enthalpy.
Compound T, 6C pH Buffer Kd,n M
DbHobs,
kJ6mol
21
Hsp90aN
ICPD 47 37 6 Pi
a 7.30 240.1
37 6.5 Pi 4.13 239.9
37 7 Pi 6.80 240.7
37 7.5 Pi 6.17 242.6
37 8 Pi 14.5 240.1
37 8.5 Pi 45. 5 243.9
37 9 Pi 84.8 264.8
37 9.5 Pi 111 250.9
37 10 Pi 400 249.7
37 10.5 Pi 699 251.5
37 11 Pi 1560 226.5
37 11.5 Pi 9620 234.4
37 6 Tris 9.35 235.9
37 6.5 Tris 2.84 233.4
37 7 Tris 10.9 230.8
37 7.5 Tris 8.20 227.1
37 8 Tris 57.5 226.5
37 8.5 Tris 86.2 222.6
37 9 Tris 88.5 226.1
37 9.5 Tris 550 229.7
37 10 Tris 510 223.1
12 7.5 Hepes 5.0 229.1
25 7.5 Hepes 8.0 228.6
37 7.5 Hepes 13.9 244.4
43 7.5 Hepes 13.3 244.1
12 7.5 Pi 7.58 233.7
25 7.5 Pi 7.19 241.1
37 7.5 Pi 10.8 251.8
43 7.5 Pi 21.7 265.4
12 7.5 Tris 8.13 214.7
25 7.5 Tris 6.71 225.0
37 7.5 Tris 10.0 232.9
43 7.5 Tris 8.23 247.8
ICPD 62 7 7.5 Hepes 0.22 212.4
12 7.5 Hepes 0.52 218.3
25 7.5 Hepes 0.27 221.2
37 7.5 Hepes 9.09 225.5
43 7.5 Hepes 3.28 234.8
7 7.5 Pi 0.31 211.9
12 7.5 Pi 3.89 214.1
25 7.5 Pi 0.19 219.4
37 7.5 Pi 5.56 218.5
43 7.5 Pi 0.85 236.6
7 7.5 Tris 0.19 210.8
12 7.5 Tris 0.33 214.2
Table 1. Cont.
Compound T, 6C pH Buffer Kd,n M
DbHobs,
kJ6mol
21
Hsp90aN
25 7.5 Tris 1.29 217.0
37 7.5 Tris 14.6 228.7
43 7.5 Tris 14.9 234.2
ICPD 34 7 7.5 Hepes 2.75 223.5
12 7.5 Hepes 6.17 225.7
25 7.5 Hepes 17.7 231.6
37 7.5 Hepes 98.0 249.5
43 7.5 Hepes 53.5 244.4
7 7.5 Pi 9.07 231.2
12 7.5 Pi 5.03 228.8
25 7.5 Pi 12.7 238.4
37 7.5 Pi 56.2 249.5
43 7.5 Pi 55.0 253.3
7 7.5 Tris 1.59 211.7
12 7.5 Tris 4.13 214.3
25 7.5 Tris 12.6 221.0
37 7.5 Tris 41.0 228.9
43 7.5 Tris 70.4 235.7
ICPD 26 12 7.5 Hepes 3.13 228.4
25 7.5 Hepes 3.65 236.9
37 7.5 Hepes 12.6 242.9
43 7.5 Hepes 17.5 253.2
12 7.5 Pi 2.59 250.1
25 7.5 Pi 7.60 242.0
37 7.5 Pi 16.2 248.4
43 7.5 Pi 18.0 261.6
12 7.5 Tris 6.17 216.2
25 7.5 Tris 6.54 227.0
37 7.5 Tris 8.36 236.6
43 7.5 Tris 6.58 244.7
Hsp90aF
ICPD 47 12 7.5 Hepes 6.06 232.6
25 7.5 Hepes 6.17 235.4
37 7.5 Hepes 8.40 239.0
43 7.5 Hepes 7.46 244.1
12 7.5 Pi 4.06 233.7
25 7.5 Pi 4.81 242.1
37 7.5 Pi 8.37 250.2
43 7.5 Pi 15.6 260.6
12 7.5 Tris 1.29 218.7
25 7.5 Tris 3.14 225.7
37 7.5 Tris 3.50 235.9
43 7.5 Tris 8.35 240.5
Repeated experiments at identical conditions in different series are shown to
illustrate the level of experimental error involved in these results.
aPi is sodium phosphate buffer. The standard deviations were about
3k J 6mol
21 for the enthalpy and up to 1.6 fold for the Kd, especially when the
binding was too tight to be measured accurately using ITC.
doi:10.1371/journal.pone.0036899.t001
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of each ligand to the protein molecule. The enthalpy of
protonation of the hydroxyl group of ICPD47, equal to
210.0 kJ/mol, was obtained by fitting all titration data and has
the uncertainty of approximately 65 kJ/mol.
Intrinsic Binding of ICPD Compounds to Hsp90 Protein
Various binding-linked reactions, usually protonation, make the
analysis of the binding reaction more complex. However, it is
necessary to be dissected in order to determine the intrinsic
binding parameters. Only the intrinsic binding parameters could
be used to correlate with the structural features of the protein-
ligand complex. In this case, intrinsic parameters refer to the
binding of electrically neutral, protonated ICPD compound.
Intrinsic thermodynamic parameters are shown in Figure 7 as a
function of temperature and listed in Table 2.
Dissection of the inhibitor binding thermodynamics into their
enthalpic and entropic contributions shows that ICPD-Hsp90
binding is driven by enthalpy and by a lesser extent –entropy
(Figure 8). The entropic component accounts for approximately
only 20% of the energy favoring binding. About 80% of the binding
energy comes from the favorable enthalpic contribution. However,
ICPD62 binding was somewhat different with enthalpic and
entropic contributions to binding being nearly equal. The Gibbs
free energiesof bindingto the full-lengthproteinandtheN-terminal
domain were similar but enthalpically more favorable to Hsp90aF
by 5.4 kJ/mol while entropically less favorable by the same amount.
The slopes of the intrinsic binding enthalpies as a function of
temperature give the intrinsic heat capacities of ICPD compound
binding to Hsp90. The heat capacity of all tested ICPD compound
binding to Hsp90aN is within the range of 2540 to
Figure 5. The observed binding constant (Kb_obs) dependence
on pH. The observed binding constants of the interaction of ICPD47
with Hsp90aN obtained using three experimental approaches: n – ITC
in phosphate buffer, % – ITC in Tris buffer, andN – TSA, all at 37uC.
There is a clear decrease in the binding affinity at higher pH. The line is
fitted according to Eq. (1) for a linked protonation event using pKa
f
=6.72. Note, that the ITC data does not provide an accurate measure of
the binding constant at pH values below 8.0 because the binding is too
tight, as shownbythedashedline drawnfor the ITCc factorequalto500.
doi:10.1371/journal.pone.0036899.g005
Figure 4. ICPD compound binding to Hsp90 by thermal shift
assay (TSA). Panel A. The raw fluorescence TSA data of ICPD47
binding to Hsp90aN at pH 7.5. The Hsp90aN thermal denaturation
transitions (Tm) were increasingly shifted upwards as the concentrations
of ICPD47 increased:N –0mM, n – 2.34 mM, & – 39.5 mM, and e –
200 mM. The lines are fits according to Eq. (5). Panel B. The melting
temperatures (Tm) from data as in Panel A plotted as a function of
added ICPD47 concentration. The line is a fit according to Eq. (6). Panel
C. The Tm TSA data as a function of the concentration of various added
compounds: , – ICPD62,N – ICPD47, e – ICPD26, & – ICPD34, and n –
17AAG. The data points are obtained from the raw data as in Panel A,
and the lines are fitted according to the model, Eq. (6). Note that
ICPD62 shifts the Tm to the greatest extent and thus the observed Kb_obs
is largest (but not the intrinsic Kb).
doi:10.1371/journal.pone.0036899.g004
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216K
21. The negative heat capacity is a signature of
hydrophobic binding reactions, and the value is approximately of
the expected magnitude for an ICPD molecule. The heat
capacities of binding slightly correlate with the burial of
hydrophobic surfaces upon binding [50], but these were not
calculated in the present study.
Figure 6. Enthalpic contributions of the binding-linked reactions are shown, including, the protonation of the compound (ICPD47 )
hydroxy group (bold and red), buffer ionization, and the intrinsic enthalpy of binding into the experimentally observed values.
doi:10.1371/journal.pone.0036899.g006
Figure 7. The intrinsic binding thermodynamic parameters (# – enthalpies, & – entropies, and m – Gibbs free energies) of ICPD47
(Panel A), ICPD62 (Panel B), ICPD34 (Panel C), and ICPD26 (Panel D) to Hsp90 plotted as a function of temperature. The intrinsic
binding parameters are listed in Table 2.
doi:10.1371/journal.pone.0036899.g007
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Binding Thermodynamic Parameters
When all intrinsic thermodynamic parameters of compound
binding to Hsp90 are determined, it is important to calculate the
differences and correlate them with the differences in functional
groups. Figure 9 shows the differences in binding parameters as
DDbX. For example, the addition of methylene group going from
ICPD26 to ICPD47 (horizontal arrow) contributes favorably
23.9 kJ/mol of the binding Gibbs free energy. Therefore,
compound ICPD47 binds more strongly to Hsp90 than ICPD26.
The methylene group is shown in green as favorably contributing
to the binding Gibbs free energy. However, its contribution to the
enthalpy of binding is slightly unfavorable.
The change of chlorine atom to the ethyl group (right vertical
arrow, going from ICPD47 to ICPD62) yielded an unfavorable
contribution both to the Gibbs free energy and enthalpy of
binding. Therefore, the ethyl group is shown in red as contributing
unfavorably to DbG.
Note that the observed binding constant as determined by TSA
was slightly greater for ICPD62 than ICPD47 (Figure 4). The
observed binding thermodynamic parameters do not correlate
with the intrinsic parameters in this case. Therefore, without
correct determination of the intrinsic thermodynamic parameters,
one would make erroneous conclusions about the contributions of
the functional groups to the binding energetics.
Discussion
Despite the difficulties involved and the large number of ITC
titrations required to carry out the full thermodynamic proton
linkage analysis, it is important to dissect the linkage to obtain the
intrinsic binding parameters of any ligand. The binding of
inhibitor to Hsp90 is a good example of a single binding-linked
protonation event for which the thermodynamic characterization
of binding would yield misleading results without the linkage
analysis.
The data listed in Table 1 illustrates the error margin for the
ITC measurements. For example, the enthalpies of ICPD47
binding to Hsp90aN in Tris buffer at 37uC and pH7.5 in two listed
repeats were 227.1 and 232.9 kJ/mol. The uncertainty of the
resultant enthalpy is about 63.0 kJ/mol. Figure 3B and 3C also
illustrate the margin of the data scatter.
The small differences in thermodynamic parameters of binding
various compounds make it difficult to put together a reliable
functional group additivity scheme. However, some trends for the
thermodynamics of binding can be visualized in Figure 9.
Beginning with ICPD26, the addition of methyl group (ICPD47)
made the binding tighter by 23.9 kJ/mol, but enthalpically less
favorable by +1.9 kJ/mol. Improved binding was fully due to an
increased entropic contribution. However, addition of a second
methoxy group (ICPD26 R ICPD34) diminished the binding
potency by about +3.1 kJ/mol. Since the enthalpies of binding
were essentially identical, the loss of potency was due to the loss of
entropy. Replacement of chlorine atom with the ethyl group
(ICPD47 R ICPD62) slightly diminished the potency by +1.5 kJ/
mol. However, the loss of favorable enthalpic contribution
(+13.7 kJ/mol) and the gain of entropic favorable contribution
(+12.2 kJ/mol) was significant.
Truncating the protein (comparing Hsp90aF and Hsp90aN) did
not affect the binding constant significantly as measured by ITC.
However, it should be kept in mind that the binding reaction is too
tight to be measured by ITC since the c factor is .500. Therefore,
more precise data for Kb_obs determination was obtained by TSA.
However, it was more difficult to determine the Kb_obs for the full
protein due to the complicated unfolding temperature curve.
Therefore, the Kb_obs data are based primarily on ITC data
comparison at pH values where reliable ITC data could be
obtained (i.e., pH 8.0–9.0).
The dissection of linked protonation events was somewhat
ambiguous. The difference between the enthalpies of binding in
phosphate and Tris buffers did not reach the n value that would be
equal to one proton being uptaken from the solution. At high pH,
Table 2. The intrinsic thermodynamic parameters of ICPD compound binding to Hsp90 at 37uC.
Protein Compound Kb,n M
21 Kd,n M
DbHintr,
kJ6mol
21
DbGintr,
kJ6mol
21
TDbSintr,
kJ6mol
21
DbSintr,
J6mol
216K
21
DbCp,
J6mol
216K
21
Hsp90aN ICPD 47 9610
8 1.1 241.2 253.2 12.0 38.6 2570
Hsp90aF ICPD 47 9610
8 1.1 246.6 253.2 6.6 21.2 2570
Hsp90aN ICPD 62 5610
8 2.0 227.5 251.7 24.2 77.9 2590
Hsp90aN ICPD 34 6610
7 16.7 243.3 246.2 2.9 9.3 2540
Hsp90aN ICPD 26 2610
8 5.0 243.1 249.3 6.2 20.0 2660
Uncertainty 61.66 61.66 63.0 62.6 64.0 614 6120
doi:10.1371/journal.pone.0036899.t002
Figure 8. Bar chart comparing relative contributions of intrinsic
enthalpies and intrinsic entropies to the Gibbs free energies of
binding of ICPD compound to Hsp90 at 376C. Note, that with the
partial exception of ICPD62, the compounds bound with major
exothermic enthalpy contribution and minor favorable entropy
contribution. Favorable contributions of both components make the
compounds such potent binders.
doi:10.1371/journal.pone.0036899.g008
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compensating protonation events could be occurring. One
possibility is that the Asp93 residue protonation may be also
linked to the binding reaction. However, such a possibility is less
likely because the two protonation events (Asp93 and OH of the
inhibitor) would sum up to make the net number n =2.
Alternatively, the Asp93 residue may be the sole protonation-
linked to binding instead of the hydroxyl group of the inhibitor.
However, such explanation is not supported by the fact that the
pKa difference between ICPD47 and ICPD62 closely correlates
with the observed binding thermodynamics as shown in Figure 6.
The structural arrangement of ICPD inhibitors in the active site
of Hsp90 may be inferred from comparison with crystal structures
of similar compounds bound to Hsp90 that are available in PDB.
ICPD inhibitors bear resorcinol group and should bind similarly to
the naturally occurring compound radicicol (PDB ID 1bgq,
energetics analyzed in [47]) or inhibitors such as 4-chloro-6-(4-
piperazin-1-yl-1h-pyrazol-3-yl)-benzene-1,2-diol (PDB ID 2ccs
[51]). One hydroxyl group of the compound makes direct
hydrogen bond with Asp93 and the nitrogen of the pyrazole ring
makes the hydrogen bond with the carbonyl oxygen of Gly97. The
chlorine atom makes hydrophobic contact with Phe138. There are
also other hydrophobic contacts. However, it also appears that
several contacts mediated by water molecules to the protein
molecule make significant contribution to the energy of binding.
Unfortunately, without crystal structures, the comparison between
the ICPD compounds is not feasible.
This study describes the thermodynamics of ICPD compound
binding to Hsp90. These compounds are enthalpically optimized
single-digit nanomolar binders of Hsp90. The compounds are
potent killers of osteosarcoma and HeLa cancer cells, thus, the
compounds may be developed into therapeutically useful Hsp90
inhibitors.
Materials and Methods
Materials
5-Aryl-4-(5-substituted-2,4-dihydroxyphenyl)-1,2,3-thiadiazole
compounds (abbreviated ICPD) were synthesized and purified as
previously described [25]. Compound stocks were prepared by
dissolving them in DMSO at 20 mM concentration. The
concentration of compounds for calorimetry experiments was
determined spectrophotometrically.
Hsp90 Constructs
Hsp90aN – the N-terminal domain of alpha Hsp90 (corre-
sponding to amino acids 1-241) was inserted into the pET21b
vector (Novagen, Madison, WI, USA) using NdeI and BamHI
restriction sites. Hsp90aF – Full length alpha Hsp90 was cloned
and purified as previously described [25].
Figure 9. Functional group contributions to the intrinsic Gibbs free energies (DbG), enthalpies (DbH), entropies (TDbS), and the heat
capacities (DbCp) of binding shown as differences (D) between the binding parameters. Groups favoring binding DbG are shown in bold
green, while unfavoring binding – in bold red. Numbers are energies in kJ/mol except for heat capacity in J6mol
216K
21. It should be noted that the
uncertainties of the values are 62.6 for the Gibbs free energies, 63.0 for enthalpies, 64.0 for entropies, and 6120 for the heat capacities. Therefore,
the differences for some contributions are within the uncertainty margins.
doi:10.1371/journal.pone.0036899.g009
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Hsp90aN protein was expressed in the Escherichia coli strain
BL21 (DE3). Bacterial cultures were grown until A550 of 0.5–0.8
was reached and the expression was induced by the addition of
1 mM IPTG. Cells were lysed by sonication. Soluble protein was
purified using an anion exchange chromatography column
containing DEAE- sepharose (GE-Healthcare Bio-Sciences AB
SE-751 84, Uppsala) followed by size exclusion chromatography
column containing Sephacryl S-200 (Pharmacia AB Laboratory
Separation Division, Uppsala Sweden).
His6-tagged Hsp90aF protein was expressed in the Escherichia
coli strain BL21 (DE3). Protein was purified using a Ni-IDA affinity
column, followed by an anion exchange chromatography column.
SDS-PAGE analysis of both Hsp90aN and Hsp90aF showed the
protein purity to be higher than 98%. Protein concentrations were
determined by UV-VIS spectrophotometry and confirmed by
standard Bradford method.
Isothermal Titration Calorimetry
The protein solutions (2–6 mM) were loaded into VP-ITC
isothermal titration calorimeter (Microcal, Inc.) cell (active cell
volume of 1.4 ml). The solution was titrated with 20–60 mM
ligand solution, 25 injections, at 3–4 minute intervals each, using
250 ml titration syringe. The stirring speed was set to 260 rpm.
Experiments were carried out at constant temperature in 7–43 uC
temperature range. The ligand solutions were prepared in the
same buffer as the protein solutions, and with the same
concentration of DMSO (usually 1%). Most titration experiments
were repeated at least twice. Some experiments, such as titrations
at intermediate pH values, were performed once. Experiments at
standard and limiting conditions of pH, temperatures, were
repeated at least three times.
Analysis of the Linked Protonation Events
A theoretical treatment demonstrating the use of ITC
measurements to dissect proton linkage from ligand binding was
given by Murphy and coworkers [35,40,52] with the application to
Hsp90 in [47]. If a protein has a single ligand-binding site and a
single proton uptake is linked to the binding process (i.e., a proton
is taken from the buffer solution), then there are four linked
processes described by the thermodynamic parameters, namely,
ligand binding to the unprotonated and protonated protein form
and proton binding to unliganded and ligand-bound protein form.
When ligand binding affects and shifts the pKa of any ionizable
group on a protein molecule, the binding and protonation events
are linked. All thermodynamic parameters, such as the Gibbs free
energies (or binding constants), enthalpies, entropies, and the heat
capacities, are additive. As it takes energy to shift the pKa, the
binding constant of a ligand would be diminished at the pH at
which the proton needs to be taken or given to the buffer. If ligand
binding is linked to the binding of a single proton, then the
observed binding constant (Kobs) and the intrinsic binding constant
(Kintr) are related by:
Kobs~Kintr
1z10pH{pKab
1z10pH{pKaf ð1Þ
Ka
b and Ka
f are the proton dissociation constants from the
liganded and unliganded protein, respectively. The change in the
number of protons bound by the protein upon binding of the
ligand (n) is the difference between the fractional saturation of
protons in the free and liganded protein:
n~fp
b{fp
f~
10pKab{pH
1z10pKab{pH {
10pKaf {pH
1z10pKaf {pH
ð2Þ
The value of n can be determined by ITC because it contributes
to the observed binding enthalpy (DbHobs):
DbHobs~DbHznDbHbuffer ð3Þ
DbH is the enthalpy that would be measured in a buffer that has
an ionization enthalpy DbHbuffer equal to zero. However, it is not
equal to the intrinsic binding enthalpy.
The intrinsic (buffer-independent) enthalpy of ICPD compound
binding was estimated from the relationship:
DbHobs~DbHintrznDbHcomplexznDbHbuffer ð4Þ
Protein Denaturation Experiments by the Thermal Shift
Assay (TSA)
The TSA was performed using Corbett Rotor-Gene 6000
(QIAGEN Rotor-Gene Q) spectrofluorimeter. The prepared
protein concentration was usually 5 mM and the ligand concen-
trations varied from 0 to 200 mM. Buffer containing 50 mM
sodium phosphate and 100 mM sodium chloride was usually used
for TSA experiments. Up to 2% (v/v) of DMSO was added to the
solution in each measurement. Reaction volume was usually 10 ml.
Unfolding of the protein was monitored by measuring the
fluorescence of the 1,8-anilinonaphthalene sulfonate (ANS), at
50–100 mM. The samples were heated at a rate of 1 uC/min. The
samples were excited with 36565 nm UV light and ANS
fluorescence emission was registered at 46065 nm light. Protein
melting temperatures were determined by fitting the protein
melting curves according to Eq. (5):
y(T)~yF,TmzmF(T{Tm)
z
(yU,Tm{yF,Tm)z(mU{mF)(T{Tm)
1ze
DUHTmzDUCp T{Tm ðÞ {T DUSTmzDUCp ln T=Tm ðÞ ðÞ ðÞ =RT
ð5Þ
y(T) is the calculated fluorescence as a function of temperature;
yF,Tm is the fluorescence of the probe bound to folded native
protein before the transition at Tm; yU,Tm is the fluorescence of the
probe bound to the unfolded protein after the unfolding transition
at Tm; mF is the slope of the fluorescence dependence on
temperature when the probe is bound to the native protein; mU
is the slope of the fluorescence dependence on temperature when
the probe is bound to the unfolded protein; DUHTm is the enthalpy
of protein unfolding at Tm; DUSTm is the entropy of protein
unfolding at Tm; DUCp is the heat capacity of protein unfolding
and is assumed to be temperature-independent over the temper-
ature range studied; R is the universal gas constant; and T is the
absolute temperature (Kelvin).
The curves in Figure 4 were fit according to Eq. (6), yielding the
binding constants for studied inhibitors.
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Lt is the total concentration of added ligand, KU,Tm is the protein
unfolding equilibrium constant at Tm; Pt is the total protein
concentration; Kb,Tm is the ligand binding constant at Tm; DUHTr
is the enthalpy of protein unfolding at Tr; Tr is the protein melting
temperature when no ligand is added; DUSTr is the entropy of
protein unfolding at Tr; DUCp is the heat capacity of protein
unfolding and is assumed to be temperature-independent over the
temperature range studied; DbHT0 is the enthalpy of ligand
binding at T0; T0 is the temperature at which the binding process
is studied (usually 37uC); DbST0 is the entropy of ligand binding at
T0; and DbCp is the heat capacity of ligand binding and is assumed
to be temperature-independent over the temperature range
studied.
The binding constant at the physiological temperature T0 is
determined using Eq. (7):
Kb,T0~e
{ DbHT0
{T0DbST0
  
=RT0 ð7Þ
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